BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Personalized medicine
,
Lipitor
,
rs4950928
,
FABP1
,
glucose metabolic process
,
Embryo
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cp 88, 059
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonis…
Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with s…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Pro…
Prevention of Inappropriate Therapies and MACCE With a Single Chamber ICD With DX Floating Dipole At…
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/N…
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combina…
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ